InosineUric AcidInosine MonophosphateInosine NucleotidesHyperuricemiaUrate OxidaseInosine PranobexAdministration, OralInosine TriphosphateHypoxanthinesHypoxanthineGoutAllopurinolAdenosinePurinesPurine-Nucleoside PhosphorylaseXanthineGout SuppressantsInosine DiphosphateGuanosineAllantoinUricosuric AgentsGlucose Transport Proteins, FacilitativeTime FactorsNucleosidesDose-Response Relationship, DrugDrug Administration SchedulePurine NucleosidesXanthine OxidaseRats, Sprague-DawleyInjections, IntravenousUnited States Food and Drug AdministrationBenzbromaroneRibonucleosidesPurine NucleotidesXanthinesUrinary CalculiDrug Administration RoutesRNA EditingRats, WistarKidney CalculiAdenine NucleotidesAdenosine A3 Receptor AntagonistsDisease Models, AnimalReceptor, Adenosine A3KidneyOxypurinolLiverChromatography, High Pressure LiquidAdenineCreatinineAdministration, IntranasalPentosyltransferasesInjections, IntraperitonealBlood PressureMycophenolic AcidBiological MarkersMice, Inbred C57BLKineticsNephrolithiasisRats, Inbred StrainsAscorbic AcidFormycinsAntioxidantsInjections, SubcutaneousPyrophosphatasesThioinosineAdenosine Deaminase InhibitorsBlood GlucoseReceptors, Adenosine A2ProbenecidFructose5'-NucleotidaseUreaAdministration, RectalMice, Inbred BALB CInjections, IntraventricularRisk FactorsAdenosine MonophosphateBiological AvailabilityHypertensionDouble-Blind MethodXanthine DehydrogenaseEnzyme InhibitorsCalcium OxalateDrug InteractionsOrganic Anion TransportersArea Under CurveInjections, IntramuscularCross-Over StudiesDiureticsAdministration, TopicalMetabolic Syndrome XInfusions, IntravenousHalf-LifeTreatment OutcomeTubercidinTumor Lysis SyndromeDogsNucleotidases